Press Releases

-- Ms. Jensen to oversee global CSR efforts and lead The Vertex Foundation -- BOSTON --(BUSINESS WIRE)--Sep. 10, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Katharine Jensen has been appointed Head of Corporate Social Responsibility (CSR). In this role, Ms.

-Data expected in late 2018 from Phase 3 studies of VX-659, tezacaftor and ivacaftor in people with one F508del mutation and one minimal function mutation and in people with two F508del mutations- -Enrollment of two Phase 3 studies of VX-445 in triple combination with tezacaftor and ivacaftor

- Approximately 1,300 patients in Australia join the thousands of patients worldwide who already have access to lumacaftor/ivacaftor - - A pathway to access for future Vertex CF medicine, tezacaftor/ivacaftor, has also been established - LONDON --(BUSINESS WIRE)--Sep.

Multi-year collaboration combines expertise in genomics, machine learning and drug discovery to identify novel targets for innovative medicines BOSTON & OXFORD, United Kingdom --(BUSINESS WIRE)--Aug. 30, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a

– Ludovic Fenaux to lead Vertex’s expanding International organization – – Simon Bedson announces retirement – LONDON --(BUSINESS WIRE)--Aug. 23, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ludovic Fenaux has been appointed Senior Vice President, International

- PBAC recommendation moves approximately 1,300 patients in Australia closer to access to lumacaftor/ivacaftor and Vertex is now working with the Australian Government to finalize a reimbursement agreement as soon as possible - LONDON --(BUSINESS WIRE)--Aug.

-- Boston Public High School Students Nora Nguyen and Sonny Mei Receive Vertex Science Leaders Scholarship to Pursue STEAM Degrees at UMass -- BOSTON --(BUSINESS WIRE)--Aug. 16, 2018-- Vertex today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride

-Data from Phase 3 ARRIVAL study support treatment with KALYDECO in children ages 12 to

- Approximately 1,300 people in the U.S. ages 2 through 5 years have two copies of the F508del mutation, the most common genetic form of the disease - BOSTON --(BUSINESS WIRE)--Aug. 7, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.

If approved, SYMKEVI ® (tezacaftor/ivacaftor) will be Vertex’s third medicine to treat the CFTR protein defect in patients with cystic fibrosis – a rare life-shortening disease LONDON --(BUSINESS WIRE)--Jul. 27, 2018-- Vertex Pharmaceuticals (Europe) Limited , today announced that the European

-Second-quarter 2018 total CF product revenues of $750 million , a 46% increase compared to $514 million in the second quarter of 2017- -Company increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&D and SG&A expense

BOSTON --(BUSINESS WIRE)--Jul. 12, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .

-SYMDEKO is Vertex’s third medicine to treat the underlying cause of CF- -Approximately 2,000 people in Canada are ages 12 and older and have two copies of the F508del mutation or at least one mutation in the CF gene that is responsive to treatment with SYMDEKO- BOSTON --(BUSINESS WIRE)--Jun.

BOSTON --(BUSINESS WIRE)--Jun. 21, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year’s Warren Alpert Foundation Prize for “transformative discoveries in the fields of genetics,

BOSTON --(BUSINESS WIRE)--Jun. 18, 2018-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the opening of its new 170,000 square foot research facility in Torrey Pines , San Diego . The new site represents a significant expansion of the Company’s research presence in the area, and

- The agreement allows for reimbursement of ORKAMBI for people with cystic fibrosis who have two copies of the F508del mutation from July 1 - - A framework for assessment and access to our future cystic fibrosis medicines is included as part of the agreement - LONDON --(BUSINESS WIRE)--Jun.

BOSTON --(BUSINESS WIRE)--Jun. 14, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex employees and The Vertex Foundation have together donated over $1 million through the Company’s new dollar-for-dollar matching gift program.

- Data from KALYDECO ® (ivacaftor) studies show the potential to modify the long-term progression of the disease - - Interim analysis of the ongoing extension study of tezacaftor/ivacaftor combination (approved in the U.S. as SYMDEKO TM ) continues to demonstrate consistent safety and sustained

BOSTON --(BUSINESS WIRE)--Jun. 6, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Wednesday, June 13, 2018 at 5:40 p.m. ET ( 2:40 p.m. PT ). The audio portion of management’s remarks will be

BOSTON and ZUG, Switzerland and CAMBRIDGE, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug